CCM
VNDA icon

Chilton Capital Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Chilton Capital Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-952
Closed -$10K – 607
2022
Q2 		$10K Buy
+952
New +$9.86K ﹤0.01% 474
2022
Q1 		– Sell
-633
Closed -$10K – 603
2021
Q4 		$10K Buy
+633
New +$11K ﹤0.01% 504

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
EIP
Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Chilton Capital Management's VNDA Position: Q3 2022 in Review

Chilton Capital Management sold out of Vanda Pharmaceuticals (VNDA) in Q3 2022, closing a stake of 952 shares — an estimated $10K sold.

Chilton Capital Management first reported a position in VNDA in Q4 2021 and held it in 2 quarters. The position peaked at $10K in Q2 2022. 178 funds tracked by Wall St. Rank hold VNDA as of Q3 2022.

  • Chilton Capital Management reported no remaining Vanda Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Chilton Capital Management sold 952 Vanda Pharmaceuticals shares in Q3 2022, an estimated $10K.
  • Chilton Capital Management first reported a position in Vanda Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • Chilton Capital Management's Vanda Pharmaceuticals position peaked at $10K in Q2 2022.
  • 178 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2022.

Based on Chilton Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.